Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

	Application Number		10700023	
	Filing Date		2003-11-03	
	First Named Inventor	Kama	akshi Sridhar	
	Art Unit		2616	
	Examiner Name	Welli	ngton Chin	
	Attorney Docket Number		139180	

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wisl	h to a	i dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Name of Patentee or Application of cited Document			Releva		Lines where ges or Relev		
	1	20030154328	A1	2003-0	8-14	Henderson et	al				
If you wisl	h to a	dd additional U.S. Publ	shed Ap	plication	citatio	n information p	lease click the Ad	d button	. Add		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Country Kind Code ² i Code ⁴		Publication Date	Name of Patente Applicant of cited Document	e or	where Re	or Relevant	+
	1										Г
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seria	al, symp	osium,	catalog, etc), o					Τs

f you wish	to a	dd additional non-patent literature document citation information please click the Add button Add EXAMINER SIGNATURE	
:	3	SRINIVASAN S H: "TTL Routing for VoliP Congestion Reduction" Communication Systems, 2002. ICCS 2002. The 8th International Conference on Nov. 25-28, 2002, Piscataway, NJ, USA, IEEE, vol. 1, 25 November 2002 (2002-11-25), pages 524-528, XP910629273	
	2	MAMMERI Z. "Delay Jitler Guarantee for Real-Time Communications with ATM Network", ATM, 1999. [CATM '99. 1999 2nd International Conference on Colmar, France 21-23 June 1999, Piscataway, NJ, USA, IEEE, US<21 June 1999-06-21, pages 146-155, XP010346202	
	1	YINGGANG Xe, et al. "Oal decording Policies Supporting Multiple Delay and Loss Requirements in ATIA Networks", Global Telecommunications Conference, 1997. (Globoom '97. JEEE Phoenix, AZ USA 3-60. 1997, New York, NY, USA, IEEE, US, vol. 2, 3 November 1997 (1997-11-03), pages 1075-1080, XP010254727.	С

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kint Code of USPTO Patient Documents at year USPTO_GOV or NEPP 9910.4. ² Eater office that issued the document, by the Novelet code (NIPO Standard ST.3) ² Strain days easily and counterful to the counter of the Company range people the series of the Emproy range people the series of number of the place of counterful to the counter of the Company range people the series of number of the place of counterful to the co

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10700023
Filing Date		2003-11-03
First Named Inventor	Kama	akshi Sridhar
Art Unit		2616
Examiner Name	Welli	ngton Chin
Attorney Docket Number		139180

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication of form a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sideosure statement. See 37 CFR 197(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.
- Fee set forth in 37 CFR 1,17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Craig A. Hoersten/	Date (YYYY-MM-DD)	2006-10-12
Name/Drint	Crois A. Hoomton	Registration Number	38017

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR. 11.4 This collection is estimated to take it hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, U.S. Operatment of Comments. P. D. 68. 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.